1. Scrip
  2. >>Business

Allo CAR-T Is Still On The Shelf As Precision Moves On

Company Pivots To In Vivo Editing

 
• By Andrew McConaghie

Precision Biosciences is exiting the allogeneic CAR-T field after four years in early clinical trials, selling off its former lead asset for just $21m.

Precision Biosciences

Precision BioSciences, which had hoped to be the first company to bring an allogeneic CAR-T to market, has announced its exit from the field with the sale of its lead asset, azercabtagene zapreleucel (azer-cel).

It is walking away from the allo CAR-T field altogether, pivoting to focus entirely on in vivo gene editing therapies, of which

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.